Long-Acting Injectables: Conference Sessions

AACAP Annual Meeting 2026

October 26–31, 2026 · Atlanta, GA

• PosterChoosing Between Aripiprazole and Paliperidone/Risperidone Long-Acting Injectables in Inpatient Psychiatric Youth

  Sungmin Hong · Natalie Burlant · Sean Lynch · Chaden Noureddine · Nishtha Ahuja · Koki Haruguchi · Caroline Wang · Ashley Sterchele

  Poster comparing selection of aripiprazole versus paliperidone/risperidone long-acting injectables in hospitalized youth.

  Antipsychotic PrescribingChild & Adolescent

APNA 40th Annual Conference

October 28–31, 2026 · Phoenix, AZ

• SymposiumSuccessfully Transitioning to Long-Acting Injectable Antipsychotics in Schizophrenia

  Symposium breakfast covering LAI antipsychotic guidelines, shared decision-making, and hands-on injection technique via 3D simulation.

  Schizophrenia & Psychosis

NEI Fall Congress 2026

November 5–8, 2026 · Colorado Springs, CO

• SymposiumTime Is Brain: Early Adoption of Long-Acting Injectables to Improve Functional Outcomes in Serious Mental Illness

  Christoph U. Correll

  Makes the case for earlier use of long-acting injectable antipsychotics in serious mental illness, with shared decision-making strategies.

  Antipsychotic PrescribingSerious Mental Illness

AAAP 37th Annual Meeting and Scientific Symposium

November 12–15, 2026 · Memphis, TN

• Oral abstractLong-Acting Injectable Antipsychotics in Serious Mental Illness with Co-Occurring Substance Use: A Retrospective Cohort Study

  Kathryn Renard

  Cohort study of long-acting injectable antipsychotic use in patients with serious mental illness and substance use.

  Serious Mental IllnessSubstance Use Disorders

• PosterFrom Methadone 200 mg/day to Brixadi: Successful Inpatient Transition Using Low-Dose Buprenorphine Induction for Persistent QTc Prolongation

  Michelle Williamson

  Case of transitioning from high-dose methadone to extended-release buprenorphine due to QTc prolongation.

  Drug Interactions & SafetyOpioid Use Disorder

• PosterFrom Opioid Avoidance to Kratom Dependence: Treatment of Kratom Use Disorder with Long-Acting Injectable Buprenorphine

  Alejandro Lopez

  Case of kratom use disorder treated with long-acting injectable buprenorphine.

  Opioid Use DisorderSubstance Use Disorders

• PosterIncidence of Precipitated Withdrawal Following Rapid Initiation of Weekly and Monthly Extended-Release Injectable Buprenorphine in Adults With Moderate-to-Severe Opioid Use Disorder Not Currently Receiving Buprenorphine: A Study Protocol

  Natalie Budilovsky-Kelley

  Study protocol on precipitated withdrawal with rapid XR buprenorphine initiation.

  Opioid Use DisorderDrug Pipeline & Clinical Trials

• PosterSubstance Use Burden and Psychiatric Readmission following Long-Acting Injectable Antipsychotic Initiation

  Angelo Chaia

  Substance use burden and readmission after starting LAI antipsychotics.

  Schizophrenia & PsychosisSubstance Use Disorders

See all 7 long-acting injectables sessions at this meeting →

Substance Use Disorders: A Comprehensive Review and Update 2027

February 15–17, 2027 · Lake Buena Vista, FL

• LectureLong-Acting Injectable Buprenorphine

  Laura G. Kehoe

  Covers long-acting injectable buprenorphine formulations.

  Opioid Use Disorder

• LectureNaltrexone Intramuscular

  Laura G. Kehoe

  Discusses intramuscular naltrexone in treatment.

  Opioid Use Disorder

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA

• SymposiumMasterClass: Operationalizing Adherence: A Practical Guide to LAI Integration in Schizophrenia Care

  Megan Ehret · Jaden Todd · Emma Nelson · Ilan Melnick · Amber Hoberg · Kevin Williams

  Compares available long-acting injectable antipsychotic formulations and offers patient-centered communication and logistics strategies for initiating, administering, and reintroducing LAIs.

  Antipsychotic PrescribingSchizophrenia & Psychosis